Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced that preparations for the ...

The Throat Cancer Foundation has expressed deep concern following the BBC’s reporting on significant disparities in HPV ...

USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 30, 2025 /PRNewswire/ -- USA News Group News Commentary - The oncology landscape is being pulled ...

An Omaha cancer patient wanted to make a special purchase while he still has time to enjoy it. But instead, may have fallen victim to an elaborate scheme.

Trinity will utilise Sunday's game against the Leopards to try and raise money for the charity that has helped Powell and his ...

Sigvotatug Vedotin is an ADC that targets integrin αvβ6-positive tumor cells. It has an engineered antibody that ensures high ...

During therapy, some cancer cells evolve to escape elimination. Newer anticancer drugs that can overcome this resistance are ...

FDA approvals and long-term study results, showcasing advancements in cancer treatments, and patient care strategies.

Imagine a drug that halts cancer without side effects or risks. That future may be a bit nearer thanks to recent research led ...

In an interview with Targeted OncologyTM, Ravi Muvner, MD, urologist at Hackensack University Medical Center, discusses how targeted therapies have changed the landscape of prostate cancer treatment.

Companies like AstraZeneca, Daiichi Sankyo, Pfizer and Merck are learning from previous setbacks in the ADC space to improve ...

A new study details the development of a nanoparticle-based system that delivers concentrated chemotherapy specifically to ...